A powerful team of collaborators bringing passionate science to the clinic

As a small company, partnering is vital to the development of our programs. Our strategy is to enter into partnerships with companies with the expertise, experience, and depth of resources to advance our programs, while retaining rights to specialty or orphan indications.

KaloBios is open to partnering its programs with partners who share out commitment to advancing our Humaneered® antibodies. These partners should share our commitment to advancing our Humaneered® monoclonal antibodies so that patients may benefit from these medicines. Given the stage of these programs, we seek partners that recognize innovation, strive for excellence, and have strong expertise in mid-to-late stage development, regulatory approval and commercialization of monoclonal antibodiesin the indications being pursued.

Technology

KaloBios’ patented proprietary Humaneered® technology platform is designed to address problems of antibody engineering.

Learn More
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue